Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

• Disease Name: Pancreatic Mucinous Cystadenoma
• MONDO ID: (if available)
• Category: Cancer

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Pancreatic Mucinous Cystadenoma. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

• What are the primary pathophysiological mechanisms?
• What molecular pathways are dysregulated?
• What cellular processes are affected?

2. Key Molecular Players

• Genes/Proteins: Which genes are causally involved or implicated?
• Chemical Entities: What metabolites, drugs, or small molecules are relevant?
• Cell Types: Which cell types are primarily affected?
• Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

• What biological processes (GO terms) are disrupted?
• Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

• Where in the cell do key processes occur?
• Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

• What is the sequence of events from initial trigger to clinical manifestation?
• Are there distinct stages or phases?

6. Phenotypic Manifestations

• What are the key clinical phenotypes?
• How do they relate to the underlying mechanisms?

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic claims
• Prioritize recent reviews and landmark papers
• Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Pathophysiology Research Report: Pancreatic Mucinous Cystadenoma (Pancreatic Mucinous Cystic Neoplasm, MCN)

0. Disease identity, definition, and current understanding

Nomenclature. “Pancreatic mucinous cystadenoma” is most commonly discussed in contemporary pathology and clinical guidelines as pancreatic mucinous cystic neoplasm (MCN), a mucin-producing cystic epithelial neoplasm. A defining criterion is that MCNs do not communicate with the pancreatic ductal system and are histologically defined by a characteristic ovarian-type subepithelial stroma. (mormul2023rarenonneuroendocrinepancreatic pages 6-8, hu2024molecularpathologyof pages 2-4)

Epidemiology and anatomy. MCNs occur predominantly in women (reported >98% female in a 2024 review) and typically arise in the pancreatic body/tail, supporting a long-standing concept of a hormonally responsive stromal niche. (hu2024molecularpathologyof pages 2-4, mormul2023rarenonneuroendocrinepancreatic pages 6-8)

Diagnostic hallmarks relevant to pathophysiology. Because MCNs lack duct communication, cyst fluid typically shows low amylase (<250 U/L), consistent with a closed cyst compartment rather than ductal mixing. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)

MONDO ID. Not identified from the retrieved evidence in this run.

1. Core pathophysiology (molecular and cellular mechanisms)

1.1 Epithelial oncogenesis: KRAS-centered initiation with stepwise tumor suppressor loss

Across recent reviews, the core mechanistic model for MCN progression is oncogenic RAS/MAPK signaling activation (usually via KRAS) followed by acquisition of alterations in tumor suppressor pathways that permit high-grade dysplasia and invasion.

• KRAS as an early driver. A 2024 molecular pathology review reports activating KRAS mutations in roughly 50–66% of MCNs and emphasizes that MCNs “rarely harbor GNAS mutations,” distinguishing them from IPMN. (hu2024molecularpathologyof pages 2-4)
• RNF43 and Wnt pathway dysregulation. Loss-of-function RNF43 alterations are reported in MCN, implicating Wnt pathway dysregulation in mucinous pancreatic cyst neoplasia. (hu2024molecularpathologyof pages 2-4)
• Late events: TP53/CDKN2A and SMAD4 in invasion. A 2014 surgical pathology/molecular genetics update summarized a canonical stepwise model: KRAS changes occur early (low-grade dysplasia), whereas TP53 and SMAD4 alterations are late and associated with invasive carcinoma. (fukushima2014mucinouscysticneoplasms pages 5-7)

A more explicitly “progression-ordered” view from a genomic review (2025) also states that SMAD4 expression is preserved in low/high-grade dysplasia but lost in a high proportion of invasive MCN carcinomas, with TP53/CDKN2A being later alterations, consistent with a multistep tumor suppressor erosion model. (yang2025genomicalterationsin pages 4-6)

1.2 Ovarian-type stroma as an active, hormone-responsive and steroidogenic microenvironment

A distinctive and mechanistically important feature of MCN is the presence of ovarian-type stroma that is not merely diagnostic but biologically active.

• Sex hormone receptor program. A 2023 review describes that ovarian-type stromal cells have “oval nuclei with spindle cell neoplasm that stain positive for oestrogen receptors,” and inhibin-positive luteinized cells may be present. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)
• Direct evidence of steroidogenesis in MCN stroma. In a comparative immunohistochemical study (20 MCNs vs 20 IPMNs), steroid hormone receptors were more frequent in MCN stroma, with SF-1 (NR5A1) H-score 112.3 ± 33.1 in MCN vs 0.9 ± 1.2 in IPMN, and steroidogenic enzymes detected in MCN stroma (P450scc 45.0%, P450c17 75.0%, 3β-HSD 65.0%). This supports a model where ovarian-type stromal cells can synthesize sex steroids in situ. (ishida2016immunohistochemicalanalysisof pages 1-2, ishida2016immunohistochemicalanalysisof pages 2-4)
• Steroidogenic machinery and stromal gene expression. The 2014 update notes that ovarian-type stroma expresses PR and ER and reports overexpression of ESR1 and STAR, plus overexpression of steroidogenic enzymes (3β-HSD, 17α-hydroxylase). (fukushima2014mucinouscysticneoplasms pages 5-7, fukushima2014mucinouscysticneoplasms pages 7-8)

Interpretation (expert synthesis). Collectively, these data support the hypothesis that MCN progression occurs in an epithelial–stromal unit where (i) epithelial KRAS-driven mucinous neoplasia and (ii) a hormone-responsive, steroidogenic stromal compartment may provide permissive growth cues (paracrine signaling, local hormone production, stromal remodeling), thereby shaping the trajectory toward dysplasia and invasion. (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7)

1.3 TGF-β/SMAD4 as a barrier whose loss cooperates with KRAS-driven transformation

TGF-β signaling via SMAD4 is repeatedly implicated as a suppressive barrier whose attenuation is associated with progression.

• Genetically defined animal model evidence. A Cancer Cell 2007 mouse model demonstrates that Kras(G12D) combined with Smad4/Dpc4 haploinsufficiency in pancreatic progenitors can induce macroscopic mucinous cystic neoplasms and invasive adenocarcinoma. Quantitatively, PanIN ductal cell proliferation was elevated (Ki-67–positive ductal cells ~17.4% ± 0.6%) compared with very low proliferation in normal-appearing ductal cells (<0.3%). (izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5)

Important nuance. The same evidence also notes that these murine cysts do not possess ovarian-like stroma and stromal cells do not express PR or ER, implying that the KRAS–SMAD4 axis can generate an MCN-like epithelial phenotype independent of the human hallmark ovarian-type stroma, and that additional (species- or context-specific) determinants likely drive formation of the ovarian-type stromal compartment in humans. (izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5)

1.4 Wnt signaling and stromal modulation

Stromal modulation of Wnt signaling is implicated in MCN biology.

• The 2014 update reports secreted frizzled-related protein (sFRP) overexpression in ovarian-type stroma and explains that sFRP “functions as a modulator of the Wnt signaling pathway,” citing work that activated Wnt signaling in stroma contributes to MCN development. (fukushima2014mucinouscysticneoplasms pages 7-8)
• Nuclear β-catenin is observed in ovarian-like stroma in a subset of MCNs in a 2022 cohort study, consistent with stromal Wnt pathway engagement. (fukumura2022intralobulardistributionof pages 7-8)

2. Key molecular players and entities

2.1 Genes/Proteins (HGNC symbols; mechanistic roles)

Key genes supported by retrieved evidence include: * KRAS (early driver; RAS/MAPK). (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) * RNF43 (Wnt regulation; implicated in mucinous cyst tumorigenesis). (hu2024molecularpathologyof pages 2-4) * TP53, CDKN2A, SMAD4 (late/advanced lesions and invasion; TGF-β suppression and cell-cycle checkpoints). (fukushima2014mucinouscysticneoplasms pages 5-7, yang2025genomicalterationsin pages 4-6) * ESR1/ER, PGR/PR, NR5A1/SF-1, steroidogenic enzymes (CYP11A1/P450scc, CYP17A1/P450c17, HSD3B/3β-HSD) in ovarian-type stroma. (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 7-8)

Table: Summary of key molecular players and dysregulated pathways in pancreatic mucinous cystic neoplasm (MCN), organized by early drivers, late/advanced alterations, and stromal biology. Citations point to recent reviews and primary studies supporting each entry.

2.2 Chemical entities / small molecules (diagnostic and mechanistic relevance)

• Glucose: intracystic glucose is lower in mucinous cysts; 2024 review cites a series where ≤50 mg/dL yielded sensitivity 92%, specificity 87%, accuracy 90% for mucinous lesions. (rogowska2024diagnosticsandmanagement pages 9-10)
• Kynurenine: metabolomic marker reported as lower in MCNs; in 2023 review, ~90% sensitivity and 100% specificity are reported for MCN discrimination in a cited study. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)
• Carcinoembryonic antigen (CEA): cyst-fluid CEA cutoff ~192–200 ng/mL gives ~80% accuracy for mucinous vs non-mucinous cysts; a 2024 review reiterates high specificity (up to 96% at >192 ng/mL) but modest sensitivity (58–63%). (mormul2023rarenonneuroendocrinepancreatic pages 8-9, rogowska2024diagnosticsandmanagement pages 9-10)
• Amylase: often low (<250 U/L) in MCN due to absence of ductal communication. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)
• CA19-9: elevated CA19-9 is treated as a concerning feature in a 2024 guideline-focused review. (rogowska2024diagnosticsandmanagement pages 9-10)

2.3 Cell types and anatomical locations

• Neoplastic epithelium: mucin-producing epithelial lining consistent with pancreatic ductal-type differentiation. (hu2024molecularpathologyof pages 2-4)
• Ovarian-type stromal cells: ER/PR/SF-1–positive mesenchymal cells with smooth muscle-like markers and steroidogenic capacity. (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7)
• Anatomy: predominance in pancreatic body/tail and lack of duct communication is central to biology and biomarker profiles. (mormul2023rarenonneuroendocrinepancreatic pages 6-8, hu2024molecularpathologyof pages 2-4)

3. Biological processes disrupted (GO-oriented)

Mechanistically supported processes include: * RAS protein signal transduction / MAPK cascade activation (KRAS). (hu2024molecularpathologyof pages 2-4) * Wnt signaling pathway dysregulation (RNF43 loss; stromal sFRP modulation; β-catenin nuclear localization). (hu2024molecularpathologyof pages 2-4, fukushima2014mucinouscysticneoplasms pages 7-8, fukumura2022intralobulardistributionof pages 7-8) * TGF-β signaling attenuation (SMAD4 loss in invasion; KRAS–SMAD4 cooperation in experimental models). (izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5, yang2025genomicalterationsin pages 4-6) * Steroid biosynthesis and hormone receptor signaling (ovarian-type stroma SF-1 and steroidogenic enzymes). (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 7-8)

4. Cellular components (GO CC-oriented)

Key cellular locations implied by the evidence: * Nucleus: ER/PR/SF-1 (transcriptional regulators) and tumor suppressors (TP53, SMAD4) exert nuclear functions. (ishida2016immunohistochemicalanalysisof pages 2-4, fukushima2014mucinouscysticneoplasms pages 5-7) * Cytoplasm/ER–mitochondrial interfaces: steroidogenic enzymes and STAR-mediated cholesterol transport underpin steroidogenesis in stromal cells. (fukushima2014mucinouscysticneoplasms pages 5-7, fukushima2014mucinouscysticneoplasms pages 7-8) * Extracellular space: secreted modulators (e.g., sFRP) affecting Wnt signaling act in the stromal compartment. (fukushima2014mucinouscysticneoplasms pages 7-8)

5. Disease progression (sequence of events and staging)

A knowledge-base-ready staging model supported by the retrieved evidence is: 1. Initiation: KRAS activation ± RNF43 alteration in mucinous epithelium; establishment of ovarian-type stroma with hormone receptor program and steroidogenic capacity. (hu2024molecularpathologyof pages 2-4, ishida2016immunohistochemicalanalysisof pages 2-4) 2. Progression: cyst enlargement/complexity and acquisition of additional genetic hits; RNF43 deficiency may potentiate KRAS hyperactivity per 2023 review. (mormul2023rarenonneuroendocrinepancreatic pages 8-9) 3. High-grade dysplasia: enrichment of TP53/CDKN2A alterations; imaging correlates (wall thickening, nodules). (fukushima2014mucinouscysticneoplasms pages 5-7, mormul2023rarenonneuroendocrinepancreatic pages 6-8) 4. Invasive carcinoma: SMAD4 loss becomes common; EGFR overexpression reported in invasive-associated MCN; invasive transformation modeled experimentally with KRAS+SMAD4 disruption. (fukushima2014mucinouscysticneoplasms pages 5-7, izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5, yang2025genomicalterationsin pages 4-6)

Table: Stage-wise summary of pancreatic mucinous cystic neoplasm (MCN) progression linking histology, key molecular alterations, stromal biology, and clinical/imaging biomarkers. This table aids GO/CC annotation and clinical translation by mapping mechanisms to observable features with citations.

6. Phenotypic manifestations (HP-oriented)

Clinical phenotypes and their mechanistic links: * Pancreatic cyst: direct result of mucinous epithelial proliferation and cyst formation. (mormul2023rarenonneuroendocrinepancreatic pages 6-8) * Pancreatitis: occurs in ~9% and may relate to local obstruction/inflammation from the cyst mass effect. (mormul2023rarenonneuroendocrinepancreatic pages 8-9) * Abdominal pain and incidental detection: clinical presentation guiding imaging and EUS evaluation within guideline pathways. (pitman2012revisedinternationalconsensus pages 1-2, mormul2023rarenonneuroendocrinepancreatic pages 8-9)

7. Current applications and real-world implementation (diagnostics and management)

7.1 Imaging and morphology-based risk stratification

Recent summaries emphasize MRI/CT + EUS for characterization and malignant-risk assessment.

• Imaging features suggesting malignancy include wall thickness ≥5 mm and mural nodules ≥9 mm, plus T2 heterogeneity and enhancing septa. (mormul2023rarenonneuroendocrinepancreatic pages 8-9, mormul2023rarenonneuroendocrinepancreatic pages 6-8)
• When mural nodules are present, a 2023 review reports CT sensitivity/specificity for malignancy of approximately 100%/98% (as cited by that review). (mormul2023rarenonneuroendocrinepancreatic pages 6-8)

7.2 Cyst-fluid biomarkers and molecular testing

• CEA: useful for mucinous vs non-mucinous distinction but not malignancy prediction; 2024 review reiterates high specificity at >192 ng/mL but modest sensitivity. (mormul2023rarenonneuroendocrinepancreatic pages 8-9, rogowska2024diagnosticsandmanagement pages 9-10)
• Glucose: widely implementable (even point-of-care) marker for mucinous cysts; performance cited above. (rogowska2024diagnosticsandmanagement pages 9-10)
• Metabolomics: kynurenine and glucose reported as promising markers for MCN discrimination. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)

7.3 Surgical thresholds and guideline-aligned management

• European-guideline–aligned recommendation: resect MCN ≥40 mm, and also resect symptomatic MCN or those with imaging signs of malignancy regardless of size. (kloth2023diagnosticstructuredclassification pages 1-2)
• A 2024 guideline-focused review similarly describes resection/referral triggers including size thresholds (>30 mm and ≥40 mm in different guideline contexts), mural nodules/solid components, duct dilation, jaundice/pancreatitis due to the cyst, elevated CA19-9, and high-grade dysplasia/cancer on cytology; it also notes that post-resection surveillance is not routinely recommended for resected MCNs without pancreatic cancer. (rogowska2024diagnosticsandmanagement pages 9-10)

8. Relevant statistics and data (recent sources prioritized)

Risk of invasion / malignant transformation. A 2023 review reports invasive carcinoma in ~4.4–16.6% of MCNs. (mormul2023rarenonneuroendocrinepancreatic pages 6-8)

Low-risk subgroup. The same 2023 review reports that MCNs ≤3 cm without suspicious features have <0.4% invasive disease, supporting de-escalation strategies in carefully selected patients where appropriate. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)

Diagnostic error. Misdiagnosis is a practical limitation; a 2023 review reports ~20% initial misdiagnosis rate for MCNs. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)

Biomarker performance examples (2023–2024 sources). * CEA cutoff ~192–200 ng/mL: ~80% accuracy for mucinous cysts. (mormul2023rarenonneuroendocrinepancreatic pages 8-9) * Glucose ≤50 mg/dL: sensitivity 92%, specificity 87%, accuracy 90% for mucinous lesions. (rogowska2024diagnosticsandmanagement pages 9-10) * Kynurenine: ~90% sensitivity and 100% specificity reported in a cited metabolomic study summarized in a 2023 review. (mormul2023rarenonneuroendocrinepancreatic pages 8-9)

9. Ontology-ready annotations (starter set)

Table: A structured mapping of key genes, processes, phenotypes, and chemical entities associated with Pancreatic MCN to standard ontologies (HGNC, GO, HP, CL, UBERON, ChEBI) to support knowledge base integration.

10. Evidence items (knowledge-base style; publication dates and URLs)

1. Mormul et al. “Rare Non-Neuroendocrine Pancreatic Tumours.” Cancers (Apr 2023). DOI: 10.3390/cancers15082216. URL: https://doi.org/10.3390/cancers15082216. Evidence includes MCN definition (ovarian-type stroma; no duct communication), invasion-rate range, imaging thresholds, and cyst-fluid biomarker performance summaries. (mormul2023rarenonneuroendocrinepancreatic pages 6-8, mormul2023rarenonneuroendocrinepancreatic pages 8-9)
2. Hu et al. “Molecular Pathology of Pancreatic Cystic Lesions with a Focus on Malignant Progression.” Cancers (Mar 2024). DOI: 10.3390/cancers16061183. URL: https://doi.org/10.3390/cancers16061183. Evidence includes KRAS frequency, RNF43, rarity of GNAS in MCN, and sex/anatomic predilection. (hu2024molecularpathologyof pages 2-4)
3. Rogowska et al. “Diagnostics and Management of Pancreatic Cystic Lesions—New Techniques and Guidelines.” Journal of Clinical Medicine (Aug 2024). DOI: 10.3390/jcm13164644. URL: https://doi.org/10.3390/jcm13164644. Evidence includes management triggers and biomarker performance (CEA, glucose; molecular testing). (rogowska2024diagnosticsandmanagement pages 9-10)
4. Kloth et al. “Diagnostic, Structured Classification and Therapeutic Approach in Cystic Pancreatic Lesions: Systematic Findings with Regard to the European Guidelines.” Diagnostics (Jan 2023). DOI: 10.3390/diagnostics13030454. URL: https://doi.org/10.3390/diagnostics13030454. Evidence includes European-guideline resection recommendation for MCN ≥40 mm and symptomatic/malignancy-suspected lesions. (kloth2023diagnosticstructuredclassification pages 1-2)
5. Ishida et al. “Immunohistochemical analysis of steroidogenic enzymes in ovarian-type stroma of pancreatic mucinous cystic neoplasms…” Pathology International (May 2016). DOI: 10.1111/pin.12406. URL: https://doi.org/10.1111/pin.12406. Evidence includes quantified ER/PR/AR/SF-1 receptor program and steroidogenic enzyme positivity rates in MCN stroma. (ishida2016immunohistochemicalanalysisof pages 2-4, ishida2016immunohistochemicalanalysisof pages 4-5)
6. Fukushima & Zamboni. “Mucinous cystic neoplasms of the pancreas: update on the surgical pathology and molecular genetics.” Seminars in Diagnostic Pathology (Nov 2014). DOI: 10.1053/j.semdp.2014.08.007. URL: https://doi.org/10.1053/j.semdp.2014.08.007. Evidence includes KRAS early vs TP53/SMAD4 late model, stromal steroidogenesis genes/enzymes, and Wnt pathway modulation in ovarian-type stroma. (fukushima2014mucinouscysticneoplasms pages 5-7, fukushima2014mucinouscysticneoplasms pages 7-8)
7. Izeradjene et al. “Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas.” Cancer Cell (Mar 2007). DOI: 10.1016/j.ccr.2007.01.017. URL: https://doi.org/10.1016/j.ccr.2007.01.017. Evidence includes genetically engineered KRAS+SMAD4 model producing MCN-like lesions and invasion, supporting KRAS–TGF-β pathway cooperation in malignant progression. (izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5)

11. Limitations of this evidence set

• PMIDs were not provided in the retrieved text snippets, so this report cites DOIs/URLs and publication dates from the retrieved sources; PMID-level indexing should be added during downstream curation.
• Some mechanistic claims (e.g., specific RNF43 prognostic utility; stromal Wnt activation) are supported here primarily through review synthesis that cites primary work; where full primary text is required for direct quotation and PMID extraction, additional retrieval is recommended. (fukushima2014mucinouscysticneoplasms pages 7-8, mormul2023rarenonneuroendocrinepancreatic pages 8-9)

References

1. (mormul2023rarenonneuroendocrinepancreatic pages 6-8): Agata Mormul, Emilia Włoszek, Julia Nowoszewska, Marta Fudalej, Michał Budzik, Anna Badowska-Kozakiewicz, and Andrzej Deptała. Rare non-neuroendocrine pancreatic tumours. Cancers, 15:2216, Apr 2023. URL: https://doi.org/10.3390/cancers15082216, doi:10.3390/cancers15082216. This article has 5 citations.

2. (hu2024molecularpathologyof pages 2-4): Yan Hu, Dan Jones, Ashwini K. Esnakula, Somashekar G. Krishna, and Wei Chen. Molecular pathology of pancreatic cystic lesions with a focus on malignant progression. Cancers, 16:1183, Mar 2024. URL: https://doi.org/10.3390/cancers16061183, doi:10.3390/cancers16061183. This article has 12 citations.

3. (mormul2023rarenonneuroendocrinepancreatic pages 8-9): Agata Mormul, Emilia Włoszek, Julia Nowoszewska, Marta Fudalej, Michał Budzik, Anna Badowska-Kozakiewicz, and Andrzej Deptała. Rare non-neuroendocrine pancreatic tumours. Cancers, 15:2216, Apr 2023. URL: https://doi.org/10.3390/cancers15082216, doi:10.3390/cancers15082216. This article has 5 citations.

4. (fukushima2014mucinouscysticneoplasms pages 5-7): Noriyoshi Fukushima and Giuseppe Zamboni. Mucinous cystic neoplasms of the pancreas: update on the surgical pathology and molecular genetics. Seminars in diagnostic pathology, 31 6:467-474, Nov 2014. URL: https://doi.org/10.1053/j.semdp.2014.08.007, doi:10.1053/j.semdp.2014.08.007. This article has 43 citations and is from a peer-reviewed journal.

5. (yang2025genomicalterationsin pages 4-6): Sen Yang, Tianqi Chen, Ming Cui, and Ya Hu. Genomic alterations in pancreatic cystic neoplasms: from molecular characterization to precision clinical management-conventional review. International journal of surgery, Jun 2025. URL: https://doi.org/10.1097/js9.0000000000002814, doi:10.1097/js9.0000000000002814. This article has 1 citations and is from a highest quality peer-reviewed journal.

6. (ishida2016immunohistochemicalanalysisof pages 1-2): Kazuyuki Ishida, Hironobu Sasano, Takuya Moriya, Yayoi Takahashi, Ryo Sugimoto, Yoshiharu Mue, Keigo Murakami, Fumiyoshi Fujishima, Yasuhiro Nakamura, Takanori Morikawa, Fuyuhiko Motoi, Takashi Suzuki, Michiaki Unno, and Tamotsu Sugai. Immunohistochemical analysis of steroidogenic enzymes in ovarian‐type stroma of pancreatic mucinous cystic neoplasms: comparative study of subepithelial stromal cells in intraductal papillary mucinous neoplasms of the pancreas. Pathology International, 66:281-287, May 2016. URL: https://doi.org/10.1111/pin.12406, doi:10.1111/pin.12406. This article has 17 citations and is from a peer-reviewed journal.

7. (ishida2016immunohistochemicalanalysisof pages 2-4): Kazuyuki Ishida, Hironobu Sasano, Takuya Moriya, Yayoi Takahashi, Ryo Sugimoto, Yoshiharu Mue, Keigo Murakami, Fumiyoshi Fujishima, Yasuhiro Nakamura, Takanori Morikawa, Fuyuhiko Motoi, Takashi Suzuki, Michiaki Unno, and Tamotsu Sugai. Immunohistochemical analysis of steroidogenic enzymes in ovarian‐type stroma of pancreatic mucinous cystic neoplasms: comparative study of subepithelial stromal cells in intraductal papillary mucinous neoplasms of the pancreas. Pathology International, 66:281-287, May 2016. URL: https://doi.org/10.1111/pin.12406, doi:10.1111/pin.12406. This article has 17 citations and is from a peer-reviewed journal.

8. (fukushima2014mucinouscysticneoplasms pages 7-8): Noriyoshi Fukushima and Giuseppe Zamboni. Mucinous cystic neoplasms of the pancreas: update on the surgical pathology and molecular genetics. Seminars in diagnostic pathology, 31 6:467-474, Nov 2014. URL: https://doi.org/10.1053/j.semdp.2014.08.007, doi:10.1053/j.semdp.2014.08.007. This article has 43 citations and is from a peer-reviewed journal.

9. (izeradjene2007kras(g12d)andsmad4dpc4 pages 2-5): Kamel Izeradjene, Chelsea Combs, Melissa Best, Aarthi Gopinathan, Amary Wagner, William M. Grady, Chu-Xia Deng, Ralph H. Hruban, N. Volkan Adsay, David A. Tuveson, and Sunil R. Hingorani. Kras(g12d) and smad4/dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer cell, 11 3:229-43, Mar 2007. URL: https://doi.org/10.1016/j.ccr.2007.01.017, doi:10.1016/j.ccr.2007.01.017. This article has 459 citations and is from a highest quality peer-reviewed journal.

10. (fukumura2022intralobulardistributionof pages 7-8): Yuki Fukumura, Yuko Kinowaki, Yoko Matsuda, Masaru Takase, Momoko Tonosaki, Masaaki Minagawa, Akio Saiura, Minoru Tanabe, Keiichi Okano, Yasuyuki Suzuki, Kota Kato, and Takashi Yao. Intralobular distribution of ovarian-like stroma in pancreatic mucinous cystic neoplasms: a discussion on its tumorigenesis. Scientific Reports, Feb 2022. URL: https://doi.org/10.1038/s41598-022-07416-9, doi:10.1038/s41598-022-07416-9. This article has 4 citations and is from a peer-reviewed journal.

11. (ishida2016immunohistochemicalanalysisof pages 4-5): Kazuyuki Ishida, Hironobu Sasano, Takuya Moriya, Yayoi Takahashi, Ryo Sugimoto, Yoshiharu Mue, Keigo Murakami, Fumiyoshi Fujishima, Yasuhiro Nakamura, Takanori Morikawa, Fuyuhiko Motoi, Takashi Suzuki, Michiaki Unno, and Tamotsu Sugai. Immunohistochemical analysis of steroidogenic enzymes in ovarian‐type stroma of pancreatic mucinous cystic neoplasms: comparative study of subepithelial stromal cells in intraductal papillary mucinous neoplasms of the pancreas. Pathology International, 66:281-287, May 2016. URL: https://doi.org/10.1111/pin.12406, doi:10.1111/pin.12406. This article has 17 citations and is from a peer-reviewed journal.

12. (rogowska2024diagnosticsandmanagement pages 9-10): Jagoda Rogowska, Jan Semeradt, Łukasz Durko, and Ewa Małecka-Wojciesko. Diagnostics and management of pancreatic cystic lesions—new techniques and guidelines. Journal of Clinical Medicine, 13:4644, Aug 2024. URL: https://doi.org/10.3390/jcm13164644, doi:10.3390/jcm13164644. This article has 20 citations.

13. (kloth2023diagnosticstructuredclassification pages 1-2): Christopher Kloth, Benedikt Haggenmüller, Annika Beck, Martin Wagner, Marko Kornmann, Jochen P. Steinacker, Nora Steinacker-Stanescu, Daniel Vogele, Meinrad Beer, Markus S. Juchems, and Stefan A. Schmidt. Diagnostic, structured classification and therapeutic approach in cystic pancreatic lesions: systematic findings with regard to the european guidelines. Diagnostics, 13:454, Jan 2023. URL: https://doi.org/10.3390/diagnostics13030454, doi:10.3390/diagnostics13030454. This article has 7 citations.

14. (pitman2012revisedinternationalconsensus pages 1-2): Martha Bishop Pitman. Revised international consensus guidelines for the management of patients with mucinous cysts. Cancer Cytopathology, 120:361-365, Dec 2012. URL: https://doi.org/10.1002/cncy.21235, doi:10.1002/cncy.21235. This article has 27 citations and is from a peer-reviewed journal.